Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

Gregory G. Schwartz(University of Colorado Denver), Nicolas Danchin(Assistance Publique – Hôpitaux de Paris), Deepak L. Bhatt(Mount Sinai Hospital), Rafael Díaz(Estudios Clínicos Latinoamérica), Margus Viigimaa(Tallinn University of Technology), Nikolaus Marx(RWTH Aachen University), Patricio López‐Jaramillo(Universidad De Santander), Philip E. Aylward(Flinders Medical Centre), Peter Sinnaeve(Brigham and Women's Hospital), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Robert Pordy(Inserm), Željko Reiner, Shaun G. Goodman(University of Toronto), Vera Bittner(University of Alabama at Birmingham), Matthew T. Roe(Clinical Research Institute), Markku S. Nieminen(Cornell University), Robert A. Harrington(Clinical Research Institute), Megan Loy(Sanofi (United States)), Andreas M. Zeiher(Goethe University Frankfurt), Harvey D. White(University of Auckland), Nina Gotcheva, Renato D. Lópes(Duke University), Petr Ošťádal(Charles University), Michael Szarek(St. Michael's Hospital), Yong Huo(Sun Yat-sen University), Heinz Drexel(ESCP Business School), Garen Manvelian(Regeneron (United States)), Pierluigi Tricoci(Duke University), Corinne Hanotin(Sanofi (France)), Vakhtang Chumburidze, Mirza Dilić(Duke University), Jay M. Edelberg(Inserm), Angèle Moryusef(Inserm), William J. Sasiela(Inserm), Guillaume Lecorps(Sanofi (United States)), Juan-Carlos Prieto, Jean‐François Tamby(Medical University of South Carolina), Philippe Gabríel Steg(Mount Sinai Hospital), Ivan Pećin, J. Wouter Jukema(Leiden University Medical Center)
Diabetes Care
March 15, 2021
Cited by 39


Related Papers